Brookline Capital Management Forecasts UNCY FY2026 Earnings

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) – Investment analysts at Brookline Capital Management raised their FY2026 earnings estimates for shares of Unicycive Therapeutics in a report released on Wednesday, November 13th. Brookline Capital Management analyst K. Raja now anticipates that the company will earn $1.88 per share for the year, up from their prior forecast of $1.85. The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($0.26) per share. Brookline Capital Management also issued estimates for Unicycive Therapeutics’ FY2027 earnings at $2.58 EPS and FY2028 earnings at $1.37 EPS.

UNCY has been the subject of a number of other research reports. Benchmark reaffirmed a “speculative buy” rating and issued a $3.00 price target on shares of Unicycive Therapeutics in a research note on Friday, September 6th. HC Wainwright reiterated a “buy” rating and set a $2.50 price target on shares of Unicycive Therapeutics in a research report on Tuesday. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $5.13.

Unicycive Therapeutics Stock Down 6.3 %

UNCY opened at $0.45 on Friday. Unicycive Therapeutics has a one year low of $0.20 and a one year high of $1.82. The business has a 50 day simple moving average of $0.43 and a two-hundred day simple moving average of $0.56.

Unicycive Therapeutics (NASDAQ:UNCY) last posted its earnings results on Wednesday, August 14th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.08.

Institutional Trading of Unicycive Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Virtu Financial LLC purchased a new stake in shares of Unicycive Therapeutics in the first quarter worth $36,000. Bleakley Financial Group LLC bought a new stake in Unicycive Therapeutics during the 3rd quarter valued at about $33,000. BVF Inc. IL raised its holdings in Unicycive Therapeutics by 70.5% in the first quarter. BVF Inc. IL now owns 3,611,601 shares of the company’s stock worth $4,984,000 after buying an additional 1,493,462 shares during the last quarter. Acuta Capital Partners LLC bought a new position in shares of Unicycive Therapeutics in the third quarter worth approximately $807,000. Finally, Walleye Capital LLC purchased a new stake in shares of Unicycive Therapeutics during the third quarter valued at approximately $2,040,000. Hedge funds and other institutional investors own 40.42% of the company’s stock.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.